Patents by Inventor Shiho Ofuchi

Shiho Ofuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KLK5 INHIBITORY PEPTIDE
    Publication number: 20220306725
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 29, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • KLK5 inhibitory peptide
    Patent number: 11292828
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: April 5, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • KLK5 INHIBITORY PEPTIDE
    Publication number: 20210340221
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Application
    Filed: May 20, 2021
    Publication date: November 4, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • KLK5 INHIBITORY PEPTIDE
    Publication number: 20210032313
    Abstract: Provided is a novel peptide. The peptide contains the amino acid sequence set forth in SEQ ID NO: 61 and inhibits a protease.
    Type: Application
    Filed: October 6, 2020
    Publication date: February 4, 2021
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi